This segment focuses on the development and commercialization of diagnostic tests for a wide range of infectious diseases, including viral, bacterial, and parasitic infections. Eurobio Scientific employs molecular biology techniques, such as PCR, and serological assays to detect and identify pathogens. R&D efforts are directed towards improving the sensitivity, specificity, and speed of diagnostic tests, as well as developing new tests for emerging infectious diseases. The company's products in this area play a crucial role in patient management, infection control, and public health surveillance. Future opportunities include expanding the portfolio of rapid diagnostic tests and developing point-of-care solutions for resource-limited settings.

Eurobio Scientific's transplantation diagnostics segment is dedicated to providing solutions for pre- and post-transplantation monitoring. This includes tests for HLA typing, antibody detection, and monitoring of immunosuppression levels. The company utilizes advanced technologies such as flow cytometry and molecular diagnostics to ensure accurate and reliable results. R&D efforts are focused on developing novel biomarkers and assays to predict and prevent transplant rejection, as well as improving patient outcomes. The AlloMap test, a gene-expression profiling based blood test for heart-transplant patients, is a key product in this segment. Future growth potential lies in expanding the range of transplant-related diagnostic tests and developing personalized monitoring strategies.

This segment encompasses the development, manufacturing, and distribution of a comprehensive range of reagents, consumables, and instruments for life science research. Eurobio Scientific offers cell culture media, molecular biology reagents, and proprietary antibodies to support research laboratories in various fields, including genomics, proteomics, and cell biology. The company's products are used in a wide range of applications, such as drug discovery, biomarker identification, and basic research. R&D efforts are focused on developing innovative reagents and technologies to improve the efficiency and reproducibility of life science experiments. Future opportunities include expanding the product portfolio to meet the evolving needs of the research community and developing customized solutions for specific research applications.